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INTRODUCTION
The chemokines (from chemotactic cytokines) comprise a 
large family of small proteins (8-14 kD molecular weights) that 
play a pivotal role in the regulation of immune cell trafficking
(1,2). Recently these signaling molecules were also implicated 
in tumor cell biology (3-5). Based on the position of the first
two cysteines (C) adjacent to the aminoterminus, chemokines 
are classified into four groups abbreviated as CXC, CC, C,
and CX3C (1-5). The biological effects of chemokines are 
mediated through their interaction with a family of heptahelical 
G-protein-coupled receptors. Based on their specific
chemokine ligands, the receptor proteins are categorized as 
CC chemokine receptors (CCR), CXC chemokine receptors 
(CXCR), C chemokine receptor (CR), and CX3C chemokine 
receptor (CX3CR) (1-5). Until now nearly 20 chemokine 
receptors and more than 50 chemokines have been identified
(http://cytokine.medic.kumamoto-u.ac.jp). 
Stromal cell-derived signals have a profound influence
on the maintenance, progression and metastatic spread of 
hematopoietic and epithelial cancers. Mesenchymal or marrow-
derived stromal cells, which constitute a large proportion of 
the non-neoplastic cells within the tumor microenvironment, 
constitutively secrete the chemokine stromal cell-derived 
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factor-1 (SDF-1/CXCL12). SDF-1 attracts cancer cells and 
vascular endothelial cells, acting through its receptor, CXCR4 
(CD184), the latter also being co-receptor for HIV entry. Thus, 
in a paracrine way, CXCR4-mediated signals stimulate tumor 
growth and tumor vascularization, respectively (reviewed in 
5). 
Here we summarize the role of SDF-1-CXCR4 signaling 
pathway in tumor biology including metastasis, growth, and 
angiogenesis. And, emphasize the significance of SDF-1-
CXCR4 pair as a novel molecular target for the treatment of 
neoplastic disease.
SDF-1-CXCR4 PAIR IN TUMOR METASTASIS 
Functions of SDF-1 and CXCR4 in cancer first were described
in metastatic breast cancer (6-9), and more recent studies 
have identified the roles of this signaling pathway in lung
cancer, prostate cancer, colorectal cancer, pancreatic cancer, 
and ovarian cancer (10-15). CXCR4 and CCR7 are highly 
expressed in human breast cancer cells, and their respective 
ligands exhibit peak levels of expression in organs representing 
the first destination of metastasis (6). These authors’ findings
indicate that chemokines and their receptors play a critical 
role in determining the metastatic destination of tumor cells. 
Accordingly, Lepteva et al (7), using small interfering RNA 
(siRNA) against CXCR4, demonstrated downregulation in 
CXCR4 expression in human MDA-MB-231 breast cancer 
cells, which resulted in a significant decrease of cancer
cell invasion, and decreased in vitro and in vivo cancer cell 
growth. Likewise, the necessity of CXCR4 in breast cancer 
metastasis by silencing of CXCR4 of breast cancer cells has 
been confirmed (8). And, an inhibitory effect of CXCR4
specific antagonists in breast cancer was recently reported
(9). Further, non-small cell lung cancer (NSCLC) specimens 
resected from patients as well as NSCLC cell lines expressed 
CXCR4 but not SDF-1, while no change in proliferation or 
apoptosis in response to SDF-1 has been demonstrated (10). 
Organs which are the preferred destination of human NSCLC 
elaborate high levels of SDF-1, and neutralizing antibodies 
can abrogate organ specific metastasis in animal model,
suggestive of critical role played by SDF-1-CXCR4 pair in 
the NSCLC metastasis (10). High CXCR4 expression in tumor 
specimens from colorectal cancer patients was also reported, 
and this associated with increased risk for local recurrence 
and/or distant metastasis (11). In line with this, multivariate 
analysis revealed that mRNACXCR4 expression level was 
significant variable for overall survival, event-free survival,
and metastasis-free survival in patients with osteosarcoma 
(12). In contrast, it was reported that CXCR4 is located in 
the nucleus and/or in the cytoplasm of tumor cells in stage 
I NSCLC, and patients whose tumors had CXCR4-positive 
nuclear staining had a significantly longer duration of survival
than patients whose tumors had no nuclear expression (13). 
Moreover, these authors found the 5-year metastasis rates were 
lower in CXCR4-positive than negative patients. As for other 
tumors, Mori et al (14) demonstrated that SDF-1-CXCR4 axis 
was involved in pancreatic cancer metastasis. 
SDF-1-CXCR4 PAIR IN TUMOR GROWTH 
There is considerable evidence that some chemokines are 
involved in tumor and normal cell survival and growth. Lapteva 
et al (7) reported breast cancer cells lacking CXCR4 expression 
proliferated at a much slower rate than control cells in vitro. 
Surprisingly, tumor cells lacking CXCR4 expression failed to 
grow in SCID mice in repeated experiments. They provided the 
first direct evidence for the essential role of CXCR4 in breast
cancer growth in vivo. Hartmann et al (15) found that SDF-1 
induced integrin activation, which resulted in an increased 
adhesion of small cell lung cancer (SCLC) cells to fibronectin
and collagen. They further revealed this was mediated by α2, 
α4, α5, and β1 integrins along with CXCR4 activation, which 
could be inhibited by CXCR4 antagonists. Stromal cells 
protected SCLC cells from chemotherapy-induced apoptosis, 
and CXCR4 inhibitors can antagonize this protection. Their 
findings suggest that activation of integrins and CXCR4
chemokine receptors co-operate in mediating adhesion and 
survival signals from the tumor microenvironment to SCLC 
cells (15). It is therefore evident that signaling mediated by 
the SDF-1-CXCR4 pathway can lead to increased survival and 
proliferation of tumor cells. As to the molecular mechanism 
upon SDF-1-CXCR4 in cell proliferation, studies from other 
groups show that SDF-1 can activate the ERK1/2 and Akt 
kinases that play an important role in regulating cancer cell 
proliferation. Barbero et al (16) demonstrated that exogenous 
SDF-1α could induce glioblastoma cells proliferation in a 
dose-dependent manner. These authors confirmed that SDF-
1α-dependent proliferation is correlated with phosphorylation 
and activation of both ERK 1/2 and Akt and that these kinases 
are independently involved in glioblastoma cell proliferation. 
Evidence that CXCR4 and SDF-1 are expressed in ovarian 
cancer cell lines was also presented (17). SDF-1α induces a 
dose-dependent proliferation in ovarian cancer cells by the 
specific interaction with CXCR4 and a biphasic activation of
ERK1/2 and Akt kinases. These findings suggest that a cross
talk between SDF-1-CXCR4 and EGFR intracellular pathways 
may link signals of cell proliferation in ovarian cancer.
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SDF-1-CXCR4 AXIS IN TUMOR VASCULARIZATION
SDF-1-CXCR4 pair is required for both normal cardiovascular 
development and postnatal vascular remodeling. Salvucci 
et al (18) showed that SDF-1 is expressed by the vascular 
endothelium from selected healthy as well as tumor tissues. 
Primary endothelial cells constitutively express SDF-1 in vitro. 
Vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) both increase the endothelial cell SDF-
1 expression. Using pertussis toxin and antibodies to inhibit 
SDF-1-CXCR-4 pathway resulted in disrupted extracellular 
matrix-dependent endothelial cell tube formation. In vivo 
study by pertussis toxin and neutralizing antibodies directed 
at SDF-1 inhibit growth factor-dependent neovascularization 
(18). Their results indicate that SDF-1-CXCR4 identifies
VEGF- and bFGF-regulated autocrine signaling systems 
that are essential regulators of endothelial cell proliferation 
and angiogenesis. Likewise, ovarian tumors strongly express 
SDF-1, which interacts with VEGF to synergistically induce 
neoangiogenesis in human ovarian cancers (19). Moreover, 
SDF-1 secreted by carcinoma-associated fibroblasts (CAF)
promoted angiogenesis by recruiting endothelial progenitor 
cells into breast cancer (20). These authors also found that 
CAF-secreted SDF-1 could stimulate tumor growth directly 
through CXCR4 expressed by carcinoma cells. Furthermore, 
SDF-1 secreted by tumor tissue can promote the migration 
of CD34+ hematopoietic cells and then promote tumor 
vascularization. Collectively, SDF-1-CXCR4 pair is related 
to metastasis, survival/growth, and vascularization of tumors 
(also see references 37-42 in Yoshioka's review on pages 35-
41 of this volume).
SDF-1-CXCR4 PAIR AS A TUMOR THERAPEUTIC TARGET
Increasing evidence supports the hypothesis that the inhibition 
of CXCR4-mediated tumorigenic signals may exert therapeutic 
effects in various cancers. Examples include small peptide 
CXCR4-specific antagonists and CXCR4 antibodies (Table).
Using RNA interference technology silence the CXCR4 in 
breast cancer resulted in impaired invasion of breast cancer 
cells in matrigel invasion assay and inhibited breast cancer 
metastasis in an animal model (8). Also, targeting SDF-1-
CXCR4 pair can attenuate in vivo tumor growth by inhibiting 
angiogenesis in a VEGF-independent manner (25). 
CONCLUSION
Recent studies have demonstrated that chemokine-chemokine 
receptor interactions, in particular those relating to SDF-
1-CXCR4, can impact at any stage of tumor biology from 
tumor development to metastasis. Molecular strategies 
aimed at inhibiting the CXCR4-mediated tumorigenic 
pathways, such as small peptide CXCR4-specific antagonists,
anti-CXCR4 antibodies, and siRNA might therefore have 
therapeutic activity in patients with various malignancies. 
As such, CXCR4 antagonists, although initially developed 
for treatment of AIDS (30,31), actually may become 
effective agents for the therapy of neoplastic disease. 
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